Status:

COMPLETED

DHEA Treatment for Sjogren's Syndrome

Lead Sponsor:

National Institute of Dental and Craniofacial Research (NIDCR)

Conditions:

Lacrimal Apparatus Disease

Salivary Gland Disease

Eligibility:

FEMALE

Phase:

PHASE2

Brief Summary

This study will evaluate the effectiveness of the male hormone dehydroepiandrosterone (DHEA) in treating Sjogren's syndrome. This autoimmune disorder, in which the immune system attacks the salivary g...

Detailed Description

Primary Sjogren's syndrome (SS) is an autoimmune disease chiefly affecting the exocrine glands. One of the most troublesome manifestations of SS is severe salivary gland dysfunction. There is no accep...

Eligibility Criteria

Females with a diagnosis of Primary Sjogren's Syndrome.

No history of breast cancer.

Key Trial Info

Start Date :

May 1 1997

Trial Type :

INTERVENTIONAL

End Date :

June 1 2002

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT00001598

Start Date

May 1 1997

End Date

June 1 2002

Last Update

March 4 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Institute of Dental And Craniofacial Research (NIDCR)

Bethesda, Maryland, United States, 20892